KIMMTRAK Sales Forecast and Market Size Analysis - 2034 Report Tracks Sales Rising from $238.7M (2023) to $310M (2024) as the First Approved TCR Therapy for Cancer Expands Globally
Dublin, Oct. 07, 2026 (GLOBE NEWSWIRE) -- "KIMMTRAK Sales Forecast and Market Size Analysis - 2034" has been added to ResearchAndMarkets.com's offering.
The report assesses the commercial outlook for KIMMTRAK, Immunocore's bispecific gp100 peptide-HLA-directed CD3 T cell engager. It covers the seven major markets (7MM) over a 2020-2034 study period.
The "KIMMTRAK Sales Forecast, and Market Size Analysis - 2034" report provides a comprehensive assessment of KIMMTRAK across the seven major markets (7MM): the United States, Germany, France, Italy, Spain, the United Kingdom, and Japan. Covering the 2020-2034 study period, the report evaluates historical performance, current market adoption, anticipated commercial expansion, and sales forecasts for approved and potential indications, including uveal melanoma and malignant melanoma.
Key Facts
A First-in-Class Immunotherapy
KIMMTRAK is the first approved T-cell receptor (TCR) therapy for cancer. It binds the gp100 peptide presented by HLA-A02:01 on tumour cells and CD3 on T cells, redirecting T cells to kill tumour cells. The report describes this as a new immunotherapy class beyond checkpoint inhibitors. KIMMTRAK is approved as monotherapy for HLA-A02:01-positive adults with unresectable or metastatic uveal melanoma (mUM).
Growth Drivers
The report identifies five factors behind KIMMTRAK's commercial momentum:
KIMMTRAK is now considered standard of care in most markets where it has launched.
Clinical and Commercial Considerations
KIMMTRAK is given intravenously, using a step-up dosing regimen followed by weekly dosing. Patients need hospitalisation and monitoring for cytokine release syndrome (CRS), which carries a boxed warning. The report examines these factors alongside pricing, cost per patient, and regional variation.
Competitive Landscape
The report reviews marketed therapies and late-stage emerging therapies in uveal melanoma and malignant melanoma, including their expected launch dates. It also assesses KIMMTRAK's market positioning, strengths, and weaknesses relative to these competitors.
Report Scope
The report covers:
Country-level forecasts are provided for the United States, Germany, France, Italy, Spain, the United Kingdom, and Japan.
For more information about this report visit https://www.researchandmarkets.com/r/tt3qv6
About ResearchAndMarkets.com
ResearchAndMarkets.com is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.